Prothena Announces Appointment of Chief Regulatory Officer
December 15 2016 - 4:05PM
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
biotechnology company focused on the discovery, development and
commercialization of novel protein immunotherapies, announced today
the appointment of Carol D. Karp as Chief Regulatory Officer. Ms.
Karp will lead Prothena’s Quality, Regulatory and Safety
organizations.
This new position adds important expertise in
line with Prothena’s continued growth as a late-stage clinical
biotechnology company with integrated research, development and
commercial capabilities.
"Carol is a highly regarded leader who has
successfully led global regulatory, quality and safety activities
across multiple therapeutic areas and all stages of product
development,” said Gene Kinney, PhD, President and Chief Executive
Officer of Prothena. “She joins Prothena as we are making steady
advances across our pipeline and continue to prepare our commercial
infrastructure in advance of key clinical data. We are delighted to
have someone with Carol’s expertise join our team to lead these key
strategic activities.”
Prior to joining Prothena, Ms. Karp was an
independent regulatory consultant with an extensive and successful
track record of leading global registration activities for
innovative new products in the biotechnology and pharmaceutical
sectors. Ms. Karp previously held executive leadership positions as
Senior Vice President of Regulatory Affairs and Compliance at
Esperion Therapeutics, and Vice President and Head of Global
Regulatory Affairs, Pharmacovigilance & Risk Management at
Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company,
where she led global regulatory affairs, regulatory operations and
CMC regulatory for a portfolio of neurodegenerative product
candidates. Prior to Janssen, Ms. Karp was Senior Vice President,
Regulatory Affairs, Quality Assurance and Drug Safety at CV
Therapeutics, which was acquired by Gilead Sciences. Ms. Karp also
held senior regulatory and scientific affairs positions at
PowderJect, VIVUS, Cygnus and Janssen Pharmaceutica.
Ms. Karp is a member of the Board of Trustees at
the University of Rochester, and an expert advisor and member of
the selection and review committees for the Stanford University
School of Medicine’s SPARK translational research program. Ms. Karp
earned her BA in biology from the University of
Rochester.
About Prothena
Prothena Corporation plc is a global, late-stage
clinical biotechnology company seeking to fundamentally change the
course of progressive diseases with its clinical pipeline of novel
therapeutic antibodies. Fueled by its deep scientific understanding
built over decades of research in protein misfolding and cell
adhesion — the root causes of many serious or currently untreatable
amyloid and inflammatory diseases — Prothena is establishing a
fully integrated research, development and commercial focus and has
advanced several drug candidates into clinical studies while
pursuing discovery of additional novel therapies. Our pipeline of
antibody-based product candidates targets a number of potential
indications including AL amyloidosis (NEOD001), Parkinson's disease
and other related synucleinopathies (PRX002), inflammatory
diseases, including psoriasis and psoriatic arthritis (PRX003), and
ATTR amyloidosis (PRX004). For more information, please visit the
company's website at www.prothena.com.
Contacts
Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com
Media: Ellen Rose
650-922-2405, ellen.rose@prothena.com
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Sep 2023 to Sep 2024